Abiraterone
Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer
June 05, 2017Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
Abiraterone delayed pain in men with metastatic prostate cancer
October 09, 2013Men with mCRPC who had not undergone previous chemotherapy reported delayed pain progression and prolonged health-related quality of life with abiraterone acetate plus prednisone, compared with prednisone alone.
Zytiga approved for metastatic prostate cancer
January 03, 2013The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
New drugs, new thinking for prostate cancer
December 21, 2012Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.
Noninvasive assay monitors treatment response in patients with metastatic prostate cancer
October 30, 2012Certain analyses of cancer cells isolated from the blood could guide decisions about the ideal treatment for a patient with metastatic prostate cancer who has stopped responding to initial therapy.
Sign Up for Free e-newsletters
ONA Articles
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Support for Exercise Programs During, After Cancer Treatment
- Oncology Clinicians Disagree on School Attendance for Children With Cancer
- False-Positive Cancer Screening Results May Increase Likelihood of Future Screenings
- Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |